NYSE:NKGN NKGen Biotech (NKGN) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free NKGN Stock Alerts $1.26 +0.01 (+0.80%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$1.23▼$1.3250-Day Range$0.84▼$2.5652-Week Range$0.78▼$12.88Volume65,176 shsAverage Volume2.49 million shsMarket Capitalization$28.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get NKGen Biotech alerts: Email Address Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About NKGen Biotech Stock (NYSE:NKGN)NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Read More NKGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKGN Stock News HeadlinesMay 2, 2024 | americanbankingnews.comNKGen Biotech (NYSE:NKGN) Shares Down 3.3% April 29, 2024 | marketwatch.comNKGen Biotech Shares Rise 15% After FDA Clears Application for Parkinson's Disease TherapyMay 12, 2024 | Weiss Ratings (Ad)The ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …April 29, 2024 | markets.businessinsider.comNKGen Biotech: FDA Clears IND Application For SNK01 NK Cell Therapy - Quick FactsApril 29, 2024 | finance.yahoo.comNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s DiseaseApril 29, 2024 | globenewswire.comNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's DiseaseApril 25, 2024 | finance.yahoo.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 25, 2024 | globenewswire.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitMay 12, 2024 | Weiss Ratings (Ad)The ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …April 24, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 22, 2024 | finance.yahoo.comReplicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingApril 22, 2024 | finance.yahoo.comWhat's Going On With Nano-Cap NKGen Biotech Stock On Monday?April 18, 2024 | finance.yahoo.comNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 18, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitApril 17, 2024 | investorplace.comNKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023April 11, 2024 | globenewswire.comNKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical ProgramsMarch 25, 2024 | globenewswire.comNKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global ConferenceMarch 22, 2024 | investing.comNKGen Biotech appoints new chairperson amid leadership shuffleMarch 6, 2024 | investorplace.comWhy Is NKGen Biotech (NKGN) Stock Up 62% Today?March 4, 2024 | finance.yahoo.comNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global ConferenceMarch 4, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global ConferenceFebruary 9, 2024 | msn.comAlana McNulty Exits NKGen Biotech’s Board and CommitteesFebruary 7, 2024 | finance.yahoo.comPassage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy CompaniesJanuary 3, 2024 | investing.comNKGen Biotech Inc (NKGN)December 29, 2023 | finance.yahoo.comNKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a TrialDecember 28, 2023 | finance.yahoo.comNKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s DiseaseDecember 27, 2023 | marketwatch.comNKGen Biotech Gets Clearance to Begin Alzheimer's Disease Treatment Trials in CanadaSee More Headlines Receive NKGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today5/12/2024Next Earnings (Estimated)7/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:NKGN Previous SymbolNYSE:NKGN CUSIPN/A CIK1845459 Webnkgenbiotech.com Phone949-396-6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,940,000.00 Net MarginsN/A Pretax Margin-76,940.53% Return on EquityN/A Return on Assets-97.14% Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.05 Sales & Book Value Annual Sales$80,000.00 Price / Sales354.38 Cash FlowN/A Price / Cash FlowN/A Book Value($2.68) per share Price / Book-0.47Miscellaneous Outstanding Shares22,500,000Free Float17,996,000Market Cap$28.35 million OptionableNot Optionable Beta0.62 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Paul Y. Song M.D. (Age 58)CEO & Chairman Comp: $36.58MMr. Sangwoo Park (Age 54)Executive Director Comp: $576kMr. James A. Graf (Age 59)Interim CFO Mr. Pierre Gagnon (Age 52)Chief Operating Officer Ms. Yoonmi KangVice President of Technical OperationsDr. Yong Man Kim Ph.D. (Age 59)Chief Scientific Officer Ms. Denise A. Chua CLSMBA, MT (ASCP), Vice President of Investor Relations & Corporate CommunicationsMs. Irene ChangVice President of Human ResourcesMr. Ryan Park C.F.A.SVP of Financial Planning & Analysis and Corporate StrategyMore ExecutivesKey CompetitorsCortexymeNASDAQ:CRTXPluriNASDAQ:PLURSurrozenNASDAQ:SRZNMiNK TherapeuticsNASDAQ:INKTProtara TherapeuticsNASDAQ:TARAView All CompetitorsInsiders & InstitutionsSequoia Financial Advisors LLCBought 16,000 shares on 5/1/2024Ownership: 0.070%University of ChicagoBought 550,000 shares on 3/14/2024Ownership: 2.513%Paul Y SongBought 75 shares on 12/6/2023Total: $249.00 ($3.32/share)Paul Y SongBought 244 shares on 11/27/2023Total: $702.72 ($2.88/share)Paul Y SongBought 100 shares on 11/21/2023Total: $280.00 ($2.80/share)View All Insider TransactionsView All Institutional Transactions NKGN Stock Analysis - Frequently Asked Questions How have NKGN shares performed in 2024? NKGen Biotech's stock was trading at $2.75 on January 1st, 2024. Since then, NKGN shares have decreased by 54.2% and is now trading at $1.26. View the best growth stocks for 2024 here. When is NKGen Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 16th 2024. View our NKGN earnings forecast. How were NKGen Biotech's earnings last quarter? NKGen Biotech, Inc. (NYSE:NKGN) posted its quarterly earnings results on Tuesday, April, 16th. The company reported ($1.68) earnings per share (EPS) for the quarter. Who are NKGen Biotech's major shareholders? NKGen Biotech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sequoia Financial Advisors LLC (0.07%). Insiders that own company stock include James A Graf and Paul Y Song. View institutional ownership trends. How do I buy shares of NKGen Biotech? Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NKGN) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
